LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

• LPX-TI641 is a novel, orally bioavailable, potent small-molecule immunomodulator that restores immune tolerance by targeting multiple pathways implicated in autoimmune diseases.

The release as fetched from its publisher. lapix.com ↗